Berlion M - Search Results

1

Characterization of the pharmacological antitumor effects of S 12363, a new vinca alkaloid.

Atassi G, Berlion M, el Oche Y, Bizzari JP. Atassi G, et al. Among authors: berlion m. Anticancer Res. 1991 Mar-Apr;11(2):975-80. Anticancer Res. 1991. PMID: 2064354

2

In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia model.

Cros S, Guilbaud N, Berlion M, Dunn T, Regnier G, Dhainaut A, Atassi G, Bizzari JP. Cros S, et al. Among authors: berlion m. Cancer Chemother Pharmacol. 1992;30(6):491-4. doi: 10.1007/BF00685604. Cancer Chemother Pharmacol. 1992. PMID: 1394807

3

Preclinical antitumor activity of a new Vinca alkaloid derivative, S 12363.

Pierré A, Kraus-Berthier L, Atassi G, Cros S, Poupon MF, Lavielle G, Berlion M, Bizzari JP. Pierré A, et al. Among authors: berlion m. Cancer Res. 1991 May 1;51(9):2312-8. Cancer Res. 1991. PMID: 2015595

4

Differential in vitro action of S-12363, a new vinblastine derivative, and of its epimer on microtubule proteins.

Wright M, Garès M, Verdier-Pinard P, Moisand A, Berlion M, Legrand JJ, Bizzari JP. Wright M, et al. Among authors: berlion m. Cancer Chemother Pharmacol. 1991;28(6):434-40. doi: 10.1007/BF00685819. Cancer Chemother Pharmacol. 1991. PMID: 1934248

5

Antitumor activity of the new vinca-alkaloid S 12363 alone or in combination with verapamil on a human multidrug resistant renal carcinoma xenograft.

Berlion M, Arvelo F, Leonce S, Bourgeois Y, Rigaudy P, Bizzari JP, Poupon MF. Berlion M, et al. In Vivo. 1993 Sep-Oct;7(5):399-405. In Vivo. 1993. PMID: 7906553

6

Evaluation of the time-schedule dependency for the cytotoxic activity of the new vinca alkaloid derivative, S 12363 (vinfosiltine).

Fischel JL, Berlion M, Formento P, Bizzari JP, Milano G. Fischel JL, et al. Among authors: berlion m. Eur J Cancer. 1993;29A(13):1890-4. doi: 10.1016/0959-8049(93)90544-p. Eur J Cancer. 1993. PMID: 8260248

7

In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative.

Pierré A, Dunn TA, Kraus-Berthier L, Léonce S, Saint-Dizier D, Régnier G, Dhainaut A, Berlion M, Bizzari JP, Atassi G. Pierré A, et al. Among authors: berlion m. Invest New Drugs. 1992 Aug;10(3):137-48. doi: 10.1007/BF00877238. Invest New Drugs. 1992. PMID: 1428723

8

Sequence-dependent cytotoxic effects of the combination of a new nitrosourea, fotemustine, with 5-fluorouracil plus folinic acid.

Fischel JL, Formento P, Berlion M, Berille J, Gioanni J, Bizzari JP, Milano G. Fischel JL, et al. Among authors: berlion m. Cancer Chemother Pharmacol. 1991;28(6):448-54. doi: 10.1007/BF00685821. Cancer Chemother Pharmacol. 1991. PMID: 1657424

9

[Quantitative cytological study of the activity of a new resistance modulator, S 9788, on human leukemic cells using multiparametric image analysis].

Oum'Hamed Z, Berlion M, Millot-Broglio C, Dufer J, Joly P, Bizzari JP, Desplaces A. Oum'Hamed Z, et al. Among authors: berlion m. Bull Cancer. 1994 Mar;81(3):203-11. Bull Cancer. 1994. PMID: 7894128 French.

10

[Cytotoxic effects of the combination of a new nitrosourea, fotemustine, combined with 5-fluorouracil and folinic acid depend on the sequence of their administration].

Fischel JL, Formento P, Berlion M, Berille J, Gioanni J, Bizzari JP, Milano G. Fischel JL, et al. Among authors: berlion m. Bull Cancer. 1992;79(1):81-90. Bull Cancer. 1992. PMID: 1520955 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters